Major and minor risk factors for cardiovascular disease in peritoneal dialysis

Peritoneal Dialysis International

Volumn 20, Issue SUPPL. 2, 2000, Pages

  Prichard, Sarah ^a  

^a ROYAL VICTORIA HOSPITAL   (Canada)

Author keywords

Cardiovascular disease; Risk factors

Indexed keywords

ANTILIPEMIC AGENT; CALCIUM; HOMOCYSTEINE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PHOSPHATE;

ARTICLE; CALCIFICATION; CALCIUM CELL LEVEL; CARDIOVASCULAR DISEASE; CORONARY ARTERY DISEASE; CORONARY RISK; DIABETES MELLITUS; DISEASE COURSE; DYSLIPIDEMIA; FAMILY HISTORY; GENDER; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERINSULINEMIA; HYPERTENSION; INFLAMMATION; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MORTALITY; OBESITY; OXIDATIVE STRESS; PERITONEAL DIALYSIS; PRIORITY JOURNAL; RISK FACTOR; VITAMIN SUPPLEMENTATION;

EID: 0034125820     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080002002s29     Document Type: Article

References (59)

1. United States Department of Health and Human Services. Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 1999 Annual Data Report. Bethesda: United States Renal Data System; 1999.
2. Canadian Organ Replacement Register. Annual Report 1998. Volume 1: Dialysis and Renal Transplantation. Ottawa, Ontario: Canadian Institute for Health Information, 1998.
3. Raine AEG. The EDTA Registry Committee. Combined report on regular dialysis and transplantation in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 2:7-35.
4. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. J Am Soc Nephrol 1998; 9(Suppl Dec):S16-23.
5. Herzog CA, Ma JZ, Collins AJ. Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N Engl J Med 1998; 339:799-805.
6. Knopp RH. Drug treatment of lipid disorders. N Engl J Med 1999; 341:498-511.
7. Gould AL, Rossouw JE, Santanello NC, Heyse JF, Furberg CD. Cholesterol reduction yields clinical benefit. Impact of statin trials. Circulation 1998; 97:946-52.
8. West of Scotland Coronary Prevention Study Group. Influence of Pravastatin and plasma lipids on clinical events in the West of Scotland Coronary Prevention Study (WOSCOPS). Circulation 1998; 97:1440-5.
9. Sacks FM, Pfeffer MA, Moye LA, Rouleau JL, Rutherford JD, Cole TG, et al. The effect of Pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. N Engl J Med 1996; 335:1001-9.
10. Prichard S, Sniderman A, Cianflone K, Marpole D. Cardiovascular disease in peritoneal dialysis. Perit Dial Int 1996; 16(Suppl 1):S19-22.
11. Sniderman AD, Cianflone K, Kwiterovich PO Jr, Hutchinson T, Barré P, Prichard S. Hyperapobetalipoproteinemia: The major dyslipoproteinemia in patients with chronic renal failure treated with chronic ambulatory peritoneal dialysis. Atherosclerosis 1987; 65(3):257-64.
12. Lamarche B, Tchernof A, Moorjani S, Cantin B, Dagenais GR, Lupien PJ, et al. Small, dense low-density lipoprotein particles as a predictor of the risk of ischemic heart disease in men. Prospective results from the Quebec Cardiovascular Study. Circulation 1997; 95:69-75.
13. Misra M, Reaveley DA, Ashworth J, Muller B, Seed M, Brown ED. Six-month prospective cross-over study to determine the effects of 1.1% amino acid dialysate on lipid metabolism in patients on continuous ambulatory peritoneal dialysis. Perit Dial Int 1997; 17:279-86.
14. Jeppessen J, Hein HO, Suadicani P, Gyntelberg F. Triglyceride concentration in ischemic heart disease. An eight-year follow-up in the Copenhagen Male Study. Circulation 1998; 97:1029-36.
15. Rosengren A, Wihelmsen L, Eriksson E, Risberg B, Wedel H. Lipoprotein (a) and coronary heart disease: A prospective case-control study in a general population sample of middle aged men. BMJ 1990; 301: 1248-51.
16. Kronenberg F, Konig P, Neyer U, Auinger M, Pribasnig A, Lang U, et al. Multicenter study of lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease treated by hemodialysis or continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 1995; 6:110-20.
17. Kim SB, Yang WS, Kang ES, Min WK, Park JS. Lipoprotein(a) and apolipoprotein(a) phenotypes in patients with end-stage renal disease. Perit Dial Int 1997; 17:236-42.
18. Guindeo C, Vega N, Fernandez AM, Palop L, Aguilar JA, Moreda A, et al. Lipoprotein(a) levels in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1996; 16(Suppl 1):S236-40.
19. Kang DH, Yoon KI, Lee SW, Kang SW, Choi KH, Lee HY, et al. Impact of nutritional status on serum lipoprotein(a) concentration in patients undergoing continuous ambulatory peritoneal dialysis. Perit Dial Int 1996; 16(Suppl 1):S241-5.
20. Koch M, Kutkuhn B, Trenkwalder E, Bach D, Grabensee B, Dieplinger H, et al. Apolipoprotein B, fibrinogen, HDL cholesterol, and apolipoprotein(a) phenotypes predict coronary artery disease in hemodialysis patients. J Am Soc Nephrol 1997; 8:1889-98.
21. Stenvinkel P, Heimbürger O, Tuck CH, Berglund L. Apo(a)-isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998; 53:1336-42.
22. Clarke R, Daly L, Robinson K, Naughten E, Cahalane S, Fowler B, et al. Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 1991; 324:1149-55.
23. Nygard O, Nordrehaug JE, Refsum H, Ueland PM, Farstad M, Vollset SE. Plasma homocysteine levels and mortality in patients with coronary artery disease. N Engl J Med 1997; 337:230-6.
24. Bachmann J, Tepel M, Raidt H, Riezler R, Graefe U, Langer K, et al. Hyperhomocysteinemia and the risk for vascular disease in hemodialysis patients. J Am Soc Nephrol 1995; 6:121-5.
25. Dennis VW, Robinson K. Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int 1996; 50(Suppl 57):S11-17.
26. Bostom AG, Lathrop L. Hyperhomocysteinemia in end-stage renal disease: Prevalence, etiology, and potential relationship to arteriosclerotic outcomes. Kidney Int 1997; 52:10-20.
27. Moustapha A, Naso A, Nahlawi M, Gupta A, Arheart KL, Jacobsen DW, et al. Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in end-stage renal disease. Circulation 1998; 97:138-41.
28. 6 concentrations. Risk factors for stroke, peripheral vascular disease, and coronary artery disease. Circulation 1998; 97:437-43.
29. Manns BJ, Burgess ED, Hyndman ME, Parsons HG, Schaefer JP, Scott-Douglas NW. Hyperhomocyste(e)inemia and prevalence of atherosclerotic vascular disease in patients with end-stage renal disease. Am J Kidney Dis 1999; 34:669-7.
30. Bostom AG, Shemin D, Lapane KL, Hume AL, Yoburn D, Nadeau MR, et al. High dose B-vitamin treatment of hyperhomocysteinemia in dialysis patients. Kidney Int 1996; 46:147-52.
31. 6 and its requirement in chronic renal failure. Kidney Int 1997; 52(Suppl 62):S56-9.
32. Vychytil A, Fodinger M, Wolfl G, Enzenberger B, Auinger M, Prischl F, et al. Major determinants of hyperhomocysteinemia in peritoneal dialysis. Kidney Int 1998; 53:1775-82.
33. van Guldener C, Janssen MJ, Lambert J, ter Wee PM, Donker AJ, Stehouwer CD. Folic acid treatment of hyperhomocysteinemia in peritoneal dialysis patients: No change in endothelial function after long-term therapy. Perit Dial Int 1998; 18:282-9.
34. Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drueke T, Massy ZA. Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int 1999; 56:2292-6.
35. Despres JP, Lamarche B, Mauriege P, Cantin B, Dagenais GR, Moorjani S, et, al. Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 1996; 334:952-7.
36. Gaudet D, Vohl MC, Perron P, Tremblay G, Gagné C, Lesiège D, et al. Relationships of abdominal obesity and hyperinsulinemia to angiographically assessed coronary artery disease in men with known mutations in the LDL receptor gene. Circulation 1998; 97:871-7.
37. Fliser P, Pacini G, Engelleiter R, Kautzky-Willer A, Prager R, Franek R, et al. Insulin resistance and hyperinsulinemia are already present in patients with incipient renal disease. Kidney Int 1998; 33:1343-7.
38. Fernstrom A, Hylander B, Moritz A, Jacobsson H, Rossner S. Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18:166-71.
39. Little J, Phillips L, Russell L, Griffiths A, Russell GI, Davies SJ. Longitudinal lipid profiles on CAPD: Their relationship to weight gain, comorbidity, and dialysis factors. J Am Soc Nephrol 1998; 9:1931-9.
40. Ross R. Mechanisms of disease. Atherosclerosis: An inflammatory disease. N Engl J Med 1999; 340:115-26.
41. Ridker PM, Glynn RJ, Hennekens CH. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction. Circulation 1998; 97:2007-11.
42. Breborowicz A, Oreopoulos DG. Evidence for the presence of chronic inflammation during peritoneal dialysis: Therapeutic implications. Perit Dial Int 1997; 17(Suppl 2):S37-41.
43. Kim KJ, Yang WS, Kim SB, Lee SK, Park JS. Fibrinogen and fibrinolytic activity in CAPD patients with atherosclerosis and its correlation with serum albumin. Perit Dial Int 1997; 17:157-61.
44. Foley RN, Parfrey PS, Harnett JD, Kent GM, Murray DC. Barre PE. Hypoalbuminemia, cardiac morbidity, and mortality in end-stage renal disease. J Am Soc Nephrol 1996; 7:728-36.
45. Blake PG. What is the problem with high transporters? Perit Dial Int 1997; 17:317-20.
46. Fried L. Higher membrane permeability predicts poorer patient survival. Perit Dial Int 1997; 17:387-401.
47. Churchill DN, Thorpe KE, Nolph KD, Keshaviah PR, Oreopoulos DG, Pagé D, for the CANUSA Peritoneal Dialysis Study Group. Increased peritoneal membrane transport is associated with decreased patient and technique survival for continuous peritoneal dialysis patients. J Am Soc Nephrol 1998; 9:1285-92.
48. Diaz-Buxo JA, Lowrie EG, Lew NL, Zhang SMH, Zhu X, Lazarus JM. Associates of mortality among peritoneal dialysis patients with special reference to peritoneal transport rates and solute clearance. Am J Kidney Dis 1999; 33:523-34.
49. Rimm EM, Stampfer MJ, Ascherio A, Giovannucci E, Colditz GA, Willett WC. Dietary intake and risk of coronary heart disease among men. N Engl J Med 1993; 328:1450-6.
50. Diaz MN, Frei B, Vita JA, Keaney JF Jr. Mechanisms of disease: Antioxidants and atherosclerotic heart disease. N Engl J Med 1997; 337:408-17.
51. Hoeschen RJ. Oxidative stress and cardiovascular disease. Can J Cardiol 1997; 13:1021-5.
52. Gey KF, Burbacher GB, Stahelin S. Plasma levels of antioxidant vitamins in relation to ischemic heart disease and cancer. Clin Nutr 1987; 45:1368-77.
53. Becker BN, Hemmelfarb J, Henrich WL, Hakim RM. Reassessing the cardiac risk profile in chronic hemodialysis patients: A hypothesis on the role of oxidant stress and other non-traditional cardiac risk factors. J Am Soc Nephrol 1997; 8:475-86.
54. Braun J, Oldendorf M, Moshage W, Heidler R, Zeitler E, Luft FC. Electron beam computed tomography in the evaluation of cardiac calcifications in chronic dialysis patients. Am J Kidney Dis 1996; 27:394-401.
55. Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium × phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am J Kidney Dis 1998; 31:607-17.
56. Levin NW, Hulbert-Shearon TE, Strawderman RL, Pert FK. Which causes of death are related to hyperphosphatemia in hemodialysis (HD) patients? [Abstract]. J Am Soc Nephrol 1998; 9:217A.
57. Orth SR, Ritz E, Schrier RW. The renal risks of smoking. Kidney Int 1997; 51:1669-77.
58. Massy ZA, Ma JZ, Louis TA, Kasiske BL. Lipid-lowering therapy in patients with renal disease. Kidney Int 1995; 48:188-98.
59. United States Department of Health and Human Services. Public Health Service, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases. USRDS 1997 Annual Data Report. Bethesda: United States Renal Data System; 1997.